Royal Bank of Canada’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-3,012
| Closed | -$10K | – | 6454 |
|
|
2018
Q3 | $10K | Sell |
3,012
-2,988
| -50% | -$9.92K | ﹤0.01% | 5395 |
|
|
2018
Q2 | $23K | Buy |
6,000
+2,346
| +64% | +$8.99K | ﹤0.01% | 4909 |
|
|
2018
Q1 | $15K | Buy |
3,654
+1,041
| +40% | +$4.27K | ﹤0.01% | 4969 |
|
|
2017
Q4 | $12K | Sell |
2,613
-6,112
| -70% | -$28.1K | ﹤0.01% | 5062 |
|
|
2017
Q3 | $62K | Buy |
+8,725
| New | +$62K | ﹤0.01% | 4564 |
|
|
2017
Q2 | – | Sell |
-54,822
| Closed | -$338K | – | 6106 |
|
|
2017
Q1 | $338K | Sell |
54,822
-1,209
| -2% | -$7.45K | ﹤0.01% | 3367 |
|
|
2016
Q4 | $328K | Buy |
56,031
+55,945
| +65,052% | +$327K | ﹤0.01% | 3423 |
|
|
2016
Q3 | $0 | Sell |
86
-18
| -17% | – | ﹤0.01% | 5818 |
|
|
2016
Q2 | $1K | Sell |
104
-2,600
| -96% | -$25K | ﹤0.01% | 5578 |
|
|
2016
Q1 | $13K | Sell |
2,704
-12,653
| -82% | -$60.8K | ﹤0.01% | 4951 |
|
|
2015
Q4 | $78K | Sell |
15,357
-92,823
| -86% | -$471K | ﹤0.01% | 4363 |
|
|
2015
Q3 | $381K | Buy |
108,180
+88,846
| +460% | +$313K | ﹤0.01% | 3240 |
|
|
2015
Q2 | $193K | Buy |
19,334
+8,271
| +75% | +$82.6K | ﹤0.01% | 3926 |
|
|
2015
Q1 | $141K | Sell |
11,063
-20,352
| -65% | -$259K | ﹤0.01% | 3987 |
|
|
2014
Q4 | $444K | Buy |
31,415
+5,846
| +23% | +$82.6K | ﹤0.01% | 3166 |
|
|
2014
Q3 | $352K | Buy |
25,569
+17,712
| +225% | +$244K | ﹤0.01% | 3275 |
|
|
2014
Q2 | $121K | Buy |
7,857
+1,285
| +20% | +$19.8K | ﹤0.01% | 3966 |
|
|
2014
Q1 | $112K | Sell |
6,572
-18,050
| -73% | -$308K | ﹤0.01% | 3987 |
|
|
2013
Q4 | $319K | Buy |
24,622
+23,599
| +2,307% | +$306K | ﹤0.01% | 3205 |
|
|
2013
Q3 | $10K | Buy |
+1,023
| New | +$10K | ﹤0.01% | 4858 |
|